vesalius biocapital: Live & Latest News Updates : Vimarsana.com

Cognivia Secures Strategic 15.5M? Funding to Empower Drug Development with AI-ML Solutions

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Cognivia Secures Strategic €15.5M Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Tonic App Raises €10.85 M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Begbies to meet expectations; McBride shines

The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- Begbies Traynor Group PLC - Manchester, England-based...

Sam Bankman-Fried's guilty verdict should be a lesson for us all

SBF’s enormous fraud was made possible with venture capital dollars.

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

SCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Nov 2, 2023--

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Developm

Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to...

Memo Therapeutics raises $27.7 million to develop antibody treatment

The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.Balance Sheet InformationCash, cash equivalents, an...